Organoid Culture Metabolite Control Patents: Who Leads 2026
Organoid Culture Metabolite Control Patents: Filing Trends and Who Leads
One filer dominates. the leading assignee holds 37 of the 92 records in scope, and the top 5 combined account for 75.0% of all filings. Filings climbed from 11 in 2017 to a peak of 26 in 2021, then fell to 3 by 2024 — an 88% drop over that three-year span. Counts for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so the apparent decline should not be read as the field cooling; it is a data-lag artefact until later years catch up.
- 1BIOMILQ INC37
- 2MITRA RXDX INDIA PTE LTD13
- 3UNIVERSITY OF CHICAGO7
- 4WHITEHEAD INST FOR BIOMEDICAL RES6
- 5ADVANCED SOLUTIONS LIFE SCIENCES LLC6
See the full organoid culture metabolite control analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in organoid culture metabolite control?
One assignee leads with 37 of the 92 records in scope, well ahead of the rest of the ranked field. The top 5 assignees combined hold 75.0% of all records, and the top 10 hold 89.1%, so the field is concentrated rather than fragmented. That leader’s portfolio centres on cultured-milk product compositions and the live-cell constructs used to produce them, which is a food-technology application of organoid metabolic control rather than a purely therapeutic one.
Is patent filing in this field growing or slowing down?
Filings rose from 11 in 2017 to a peak of 26 in 2021, then fell to 3 by 2024 — an 88% decline over that span, using the last year that can be treated as complete. Figures for 2025 and 2026 are still low, but that reflects publication lag of roughly 18 months rather than a real drop-off, so it is premature to call the field in decline based on the most recent two years alone. A fair read is that filing activity has cooled from its 2021 peak, with the post-2024 picture still forming.
What technology areas overlap most with organoid metabolite control patents?
Nearly all records (98.9%) sit under C12N, the core cell-culture and genetic engineering classification, which is expected given the search scope. Below that, C07K peptide and protein claims appear on 32.6% of records and A61K medicinal preparation claims on 30.4%, marking a therapeutic organoid branch. A23C dairy product claims (25.0%) and C12M bioreactor apparatus claims (20.7%) mark a separate cultured-food branch — the two together suggest metabolite-control techniques are being claimed both for drug development and for food production.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Organoid Culture Metabolite Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.